PEi Program

Antabio’s Pseudomonas elastase inhibitor (PEi) program is developing an inhaled drug targeting a key virulence factor of Pseudomonas aeruginosa involved in pathogenesis and persistence. The drug will be administered via nebuliser as an alternative or adjunct to existing antibiotic therapy for the treatment of P. aeruginosa infections in chronic respiratory disease, such as cystic fibrosis, bronchiectasis and COPD. Preclinical development is in progress.